Streetbeat News

APGN

Apexigen Inc

Employees

Industry

Research and Development in Biotechnology

apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by apximab™, the company’s proprietary antibody drug discovery platform. its lead immuno-oncology drug candidate, apx005m, is a potent immune-activating antibody against cd40 currently in phase 2 clinical development.

Open

0.36

Mkt cap

9.6M

Volume

94K

High

0.40

P/E Ratio

-0.23

52-wk high

8.28

Low

0.36

Div yield

N/A

52-wk low

0.33

EF Hutton analyst Tony Butler reiterates a Hold rating on Apexigen (NASDAQ:APGN) and maintains a $0.64 price target.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 3:42 pm

Pyxis Oncology (NASDAQ:PYXS) has agreed to acquire Apexigen (NASDAQ:APGN) in an all-stock transaction valued at $0.64 per share, with a total enterprise value of $16 million. The deal is expected to close by mid-2023, and the combined company will trade under the ticker symbol PYXS.

Portfolio Pulse from Vandana Singh

May 24, 2023 | 6:28 pm

In Wednesday's mid-day session, Minerva Surgical, EpicQuest Education Group, and Enveric Biosciences saw significant gains after receiving patents and signing agreements. Meanwhile, America's Car-Mart shares dropped by 11.8% following weak quarterly earnings.

Portfolio Pulse from Lisa Levin

May 24, 2023 | 4:48 pm

Pyxis Oncology (NASDAQ:PYXS) has announced a $16 million acquisition of Apexigen (NASDAQ:APGN), expected to be completed in the second half of 2023. Pyxis Oncology will give Apexigen $16 million in stock in exchange for APGN stock.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 4:21 pm

Apexigen's shares are trading higher after Pyxis Oncology announced its plans to acquire the company.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:36 pm

Pyxis Oncology is set to acquire Apexigen in an all-stock transaction, valuing Apexigen shares at $0.64 each.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 10:48 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.